摘要生长刺激表达基因2蛋白（ST2）是白细胞介素1受体/Toll样受体超家族的成员，主要分为可溶性ST2（sST2）和跨模型ST2（ST2L）两种类型，白细胞介素33（IL-33）是其内源性配体。IL-33/ST2L通路具有抗动脉粥样硬化、抗心肌肥厚、抗心肌纤维化等多种心血管保护作用，而sST2作为一种诱骗受体，与IL-33结合则可以阻断上述生物学作用。近来研究发现，sST2作为一种新型生物标志物，在多种心血管疾病的诊治中发挥重要作用。本文将对sST2在冠心病及心力衰竭中的临床研究及进展做一综述。

abstractsThe growth stimulation expression gene 2 protein (ST2) is a member of the interleukin 1 receptor/Toll-like receptor superfamily with two main types, soluble ST2 (sST2) and ligand ST2 (ST2L) and interleukin 33 (IL-33) is its endogenous ligand. IL-33/ST2L pathway has a variety of cardiovascular protective effects such as anti-atherosclerosis, anti-myocardial hypertrophy and anti-myocardial fibrosis, while sST2, as a decoy receptor, can block these biological effects by binding to IL-33. Recent studies have found that sST2, as a novel biomarker, plays an important role in the diagnosis and treatment of a variety of cardiovascular diseases. Thus, this paper will review the clinical application and research progress of sST2 in coronary heart disease and heart failure.